title: [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
abstract: Aflibercept (Zaltrap(®) : aflibercept is a recombinant fusion protein, anti-angiogenic, which blocks activation of VEGF and PIGF receptor), obtained its European approval February 2(nd), 2013 in combination with Folinic Acid, 5FU and irinotecan (FOLFIRI) in adults with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen. This decision was based on the efficacy and safety results of the VELOUR Phase III trial. This study showed an improved overall survival, with the combination of aflibercept and FOLFIRI versus FOLFIRI + placebo (13.5 months vs 12.06 months ; HR = 0,817, IC à 95 %, 0,714 à 0,935 ; p = 0,003 2). Adverse effects reported with aflibercept combined with FOLFIRI included the specific anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities. Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA and a EMEA approval for patients with metastatic colorectal cancer.
authors.affiliation: Hôpital Saint-Antoine, Service d'oncologie médicale, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: André
authors.forename: Benoist
authors.initials: B
authors.lastname: Chibaudel
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017277:Drug Approval; D005060:Europe; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: aflibercept; anti-angiogenic; metastatic colorectal cancer